Highlights von der ASCO-Jubiläumstagung 2014 – Neue Therapiedaten zum Brustkrebs

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Univ.-Doz. Dr. Susanne Taucher

Abteilung für Gynä­kologie und Geburtshilfe, LKH Hall in Tirol


1 Harold J. Burstein: Fifty Years of Systemic Therapy for Breast Cancer: From One Size Fits All to Tailored Therapy. 2014 Educational Book

2 Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol 2014; 32: 5s (Suppl.; Abstr. LBA1)

3 First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014; 32: 5s (Suppl.; Abstr. LBA4)

4 Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 2014; 32:5s (Suppl.; Abstr. LBA505)


GA 04|2014

Herausgeber: em. o. Univ.-Prof. Dr. Sepp Leodolter, Universitätsklinik für Frauenheilkunde, Wien
Publikationsdatum: 2014-09-17